T&R Biofab , a regenerative medicine specialist company, announced on the 20th that it has signed a memorandum of understanding (MOU) with Asrigen, a specialist in orthopedic regenerative medicine, for the research, development, and commercialization of new advanced orthopedic medical devices.
This agreement aims to combine the technologies and clinical capabilities of both companies to jointly develop cutting-edge orthopedic medical devices and establish a product development system that reflects clinical applicability from the initial design stage. After development is complete, the two companies plan to pursue clinical application and commercialization.
T&R Biofab possesses 3D printing-based biomaterial design and manufacturing technology, experience in developing regenerative medical devices, and medical device licensing capabilities. Asrigen, founded by Professor Wang Jun-ho of the Department of Orthopedics at Samsung Medical Center, has accumulated research and clinical experience in knee joint reconstruction and meniscus treatment. Based on its non-clinical and clinical research expertise in orthopedic medical devices and its medical network, Asrigen is developing a functional regenerative treatment platform for patients with meniscus injuries.
The two companies will jointly research and develop a medical device for regenerative therapy for patients with meniscus injuries, with the primary development goal being the development of a meniscus-related device. The meniscus is responsible for shock absorption and load distribution in the knee joint, and damage to it can lead to degenerative arthritis. Existing treatments are limited to suturing or partial resection, and demand for medical solutions that can induce functional regeneration is steadily increasing.
“We expect that combining Asrigen’s clinical insights in the field of knee joint reconstruction with our 3D printing-based regenerative medical device development capabilities will enable us to make progress in the development of innovative orthopedic medical devices aimed at functional regeneration,” said Sim Jin-hyung, Chief Technology Officer (CTO) of T&R Biofab.
- See more related articles
You must be logged in to post a comment.